BUZZ - UBS raises its target price for Biogen due to the catalyst in its late-stage R&D pipeline; stock price rises
路透社2026/10/09 16:16October 9 - ** Shares of pharmaceutical company Biogen (BIIB.O) rose 2.4% to $223.71 ** UBS raised its price target from $240 to $270 and reiterated a "Buy" rating ** Third-quarter revenue is expected to reach $2.69 billion, with earnings per share (EPS) at $2.11, both slightly above market consensus ** Third-quarter sales of Alzheimer's drug Leqembi are predicted to be $200 million, in line with market expectations, and the recently launched subcutaneous formulation is projected to become a key growth driver starting in 2027 ** Biogen is now more optimistic about ophthalmology drug Syfovre than it was at the time of acquiring Apellis (link), and is optimizing its commercialization strategy ** Late-stage clinical data for lupus drug litifilimab due later this year and data on cutaneous lupus erythematosus expected in the first half of 2027 are seen as key catalysts ** Furthermore, late-stage clinical results for kidney drug felzartamab, expected in the first half of 2027, are anticipated to provide further upside, and clinical trials by Eli Lilly (LLY.N) for presymptomatic Alzheimer's may produce positive spillover effects ** Including intraday fluctuations, the stock is up 26.3% year-to-date.
October 9 - ** Shares of pharmaceutical company Biogen (BIIB.O) rose 2.4% to $223.71
** UBS raised its target price from $240 to $270 and reiterated a “Buy” rating
** Third quarter revenue is expected to reach $2.69 billion and earnings per share (EPS) $2.11, both slightly above market consensus
** Leqembi, the Alzheimer’s disease treatment, is expected to generate $200 million in third quarter sales, in line with market consensus, and the recently launched subcutaneous formulation is expected to become a key growth driver starting in 2027
** Noted that Biogen is more optimistic about ophthalmology drug Syfovre than when acquiring Apellis (link), and is optimizing its launch strategy
** Late-stage clinical data for the lupus drug litifilimab coming later this year, as well as data for cutaneous lupus erythematosus in the first half of 2027, will be key catalysts
** In addition, late-stage clinical data for the kidney disease drug felzartamab, to be announced in the first half of 2027, is expected to provide upside, while Eli Lilly (LLY.N)’s clinical trials for asymptomatic Alzheimer’s disease could result in positive spillover effects
** Including intraday volatility, the stock has risen 26.3% year to date
(To aid non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text. Automated translations are provided solely for reader convenience. Reuters accepts no responsibility for any harm or losses arising from use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Update: Equities Rise Intraday as Traders Parse Consumer Sentiment Survey
01:37 PM EDT, 10/09/2026 (MT Newswires) -- (Updates with latest market prices and developments.) US benchmark equity indexes were higher intraday as investors evaluated a survey on consumer sentiment. The Dow Jones Industrial Average was up 0.8% at 51,628.8 after midday Friday, while the Nasdaq Composite and the S&P 500 rose 0.6% each to 27,352.4 and 7,809.5, respectively. Barring communication services, all sectors were in the green, led by real estate. US consumer sentiment fell in October as the one- and five-year inflation expectations reached their highest levels since May, preliminary results of a University of Michigan survey showed Friday. "While year-ahead expectations for personal finances and business conditions crept up slightly, buying conditions for durables plummeted amid high prices and borrowing costs," Surveys of Consumers Director Joanne Hsu said. "Frustration over cost-of-living continues to mount, as consumers across the political spectrum believe that the trajectory of the economy has weakened since the beginning of the year." Markets are currently pricing in a nearly 81% probability that the Federal Reserve will keep its benchmark rate steady later this month, with the remaining odds in favor of a second consecutive 25-basis-point hike, as the central bank looks to tame inflation, according to the CME FedWatch tool. West Texas Intermediate crude was down 0.4% at $91.17 a barrel intraday, while Brent lost 0.5% to $103.81. The 10-year US Treasury yield was up 1.5 basis points at 5.25%, while the two-year rate increased 3.9 basis points to 4.8%. In company news, SpaceX (SPCX) shares were up 0.5%. The rocket and satellite company said late Thursday it agreed to acquire a nationwide low-band spectrum portfolio from investment firm Grain Management as it seeks to establish Starlink Mobile as a major US mobile carrier. T-Mobile US (TMUS) shares sank 13% intraday Friday, the worst performer on the S&P 500, followed by AT&T (T) and Verizon Communications (VZ), which fell 10% and 9.8%, respectively.
Ameren declares quarterly dividend of $0.75 a share
Ameren declared a quarterly cash dividend of 75 cents per common share. Dividend payable Dec. 31, 2026. Shareholders of record as of Dec. 8, 2026 will receive the dividend. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ameren Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610091331PR_NEWS_USPR_____CG68019) on October 09, 2026, and is solely responsible for the information contained therein.
McEwen’s $55M Ontario asset sale fuels gold growth plans
US Stock Market Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuts on the US stock market; shares fall over 10% after opening
As of press time, the stock has dropped more than 10%, trading at $10.77.
Crypto prices
More
